Individualizing primary prophylaxis in patients with hemophilia A and B, adherence and new products.
Blood Coagul Fibrinolysis
; 34(S1): S12-S14, 2023 Jun 01.
Article
em En
| MEDLINE
| ID: mdl-37254724
ABSTRACT
The purpose of prophylaxis in hemophilic patients is to prevent bleeding. The latest guidelines of the World Hemophilia Federation recommend that all patients with a severe hemorrhagic phenotype should receive prophylactic treatment, defined as the regular administration of therapeutic products (either factor concentrates or nonfactor replacement treatments). These products are aimed at preserving hemostasis and preventing bleeding, especially into joints. The guidelines also stipulate that prophylaxis should allow patients with hemophilia to lead healthy and active lives, participating in most physical and social activities, similar to the nonhemophilic population.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Hemofilia B
/
Hemofilia A
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article